Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6233324 | 0.98 | CYP2D6 (0.50) | CYP2D6MC4RLTA4HCHRM2CHRM1 | |
| SCHEMBL8725283 | 0.84 | CYP2D6 (0.42) | CYP2D6MC4RLTA4HCHRM2CHRM1 | |
| SCHEMBL14938679 | 0.82 | CYP2D6 (0.47) | CYP2D6MC4RLTA4HOPRM1OPRD1 | |
| SCHEMBL1855362 | 0.82 | CHRM2 (0.53) | CYP2D6MC4RCHRM2CHRM1OPRM1 | |
| SCHEMBL28442102 | 0.80 | CYP2D6 (0.44) | CYP2D6MC4RCHRM2CHRM1OPRM1 | |
| SCHEMBL16982012 | 0.78 | CYP2D6 (0.56) | CYP2D6MC4RLTA4HCHRM2CHRM1 | |
| SCHEMBL7097730 | 0.78 | CYP2D6 (0.83) | CYP2D6MC4RLTA4HCHRM2CHRM1 | |
| SCHEMBL8983562 | 0.78 | CYP2D6 (0.83) | CYP2D6MC4RLTA4HCHRM2CHRM1 | |
| SCHEMBL8983627 | 0.78 | CYP2D6 (0.83) | CYP2D6MC4RLTA4HCHRM2CHRM1 | |
| SCHEMBL20899319 | 0.77 | CYP2D6 (0.50) | CYP2D6MC4RLTA4HCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018151678-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-08-23 | — | — | WO | claimed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | disclosed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3694860-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | Syros Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2019-10-22 | — | — | US | disclosed |
| WO-2019074962-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20180362532-A1 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | US | disclosed |
| EP-3157922-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2018-11-28 | — | — | EP | disclosed |
| WO-2013068458-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-05-16 | — | — | WO | disclosed |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | CASH BRANDON (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130018151-A1 | METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE-BASED POLYMER, AND METHOD FOR PRODUCING VULCANIZED POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-17 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| EP-2166850-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | High Point Pharmaceuticals, LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2014656-A2 | New heteocyclic h3 antagonists | TRANSTECH PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | CYP2D6 4525/4885MC4R 2179/4885LTA4H 2609/4885 |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | CYP2D6 4525/4885MC4R 2179/4885LTA4H 2609/4885 |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | CYP2D6 1052/4885MC4R 4044/4885LTA4H 4543/4885 |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HRH3, HRH4, HRH2 | CYP2D6 1681/4885MC4R 265/4885LTA4H 821/4885 |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CYP2D6 2205/4885MC4R 3093/4885LTA4H 356/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | CYP2D6 4525/4885MC4R 2179/4885LTA4H 2609/4885 |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2B | CYP2D6 1847/4885MC4R 2391/4885LTA4H 2145/4885 |
| US-20180362532-A1 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | PI4KA, PI4KB, PI4K2B | CYP2D6 1847/4885MC4R 2391/4885LTA4H 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.